CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Baker BROS. Advisors LP

Baker BROS. Advisors LP grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 55.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,308,011 shares of the company’s stock after purchasing an additional 464,936 shares during the period. CRISPR Therapeutics makes up about 0.5% of Baker BROS. Advisors LP’s holdings, making the stock its 23rd largest holding. Baker BROS. Advisors LP owned about 1.53% of CRISPR Therapeutics worth $51,483,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CRSP. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Nordea Investment Management AB lifted its holdings in CRISPR Therapeutics by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 125,400 shares of the company’s stock worth $4,913,000 after buying an additional 5,300 shares in the last quarter. Capital Market Strategies LLC purchased a new position in CRISPR Therapeutics in the 4th quarter valued at approximately $461,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of CRISPR Therapeutics by 19.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 36,139 shares of the company’s stock worth $1,422,000 after acquiring an additional 5,898 shares in the last quarter. Finally, Highline Wealth Partners LLC purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $39,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on CRSP. Truist Financial boosted their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Bank of America reduced their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Royal Bank of Canada lowered their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. Citigroup reduced their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a report on Tuesday, February 18th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Stock Up 1.4 %

CRSP opened at $38.25 on Friday. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The business has a 50 day moving average price of $38.97 and a two-hundred day moving average price of $43.18. The company has a market cap of $3.30 billion, a PE ratio of -8.75 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 9,973 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares of the company’s stock, valued at $7,673,353.80. This represents a 5.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Greene bought 7,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 26th. The stock was acquired at an average cost of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.